PND53 The Patient-Reported Burden of Impaired Walking in Multiple Sclerosis  by Moorcroft, E. et al.
positively correlated with one another (0.20r0.73), and significantly negatively
correlated with PDDS scores (-0.82r-0.07). The physical functioning domain cor-
related most strongly with PDDS scores (r-0.82, p0.001). Strong correlations
were also noted among the role-physical (r-0.58, p0.001), social functioning
(r-0.37, p0.001), and bodily pain (r-0.28, p0.001) domains. The domains cor-
relating most weakly with PDDS scores were vitality (r-0.23, p0001) and mental
health (r-0.07, p0.03). CONCLUSIONS: As expected, the patient-rated PDDS
scores were more strongly associated with domains related to physical health
status. To capture the broader psychosocial impact of MS on patient HRQL, addi-
tional patient-reported outcomes need to be utilized.
PND52
RESPONSIVENESS OF THE MULTIPLE SCLEROSIS INTERNATIONAL QUALITY OF
LIFE AND SHORT FORM-36 QUESTIONNAIRES TO EXPANDED DISABILITY
STATUS SCALE SCORE CHANGES IN SUBJECTS WITH MULTIPLE SCLEROSIS:
FINAL 24-MONTH RESULTS FROM AN INTERNATIONAL OBSERVATIONAL
STUDY
Fernandez O1, Baumstarck-Barrau K2, Butzkueven H3, Flachenecker P4, Idiman E5,
Pelletier J2, Stecchi S6, Verdun di Cantogno E7, Milner A7, Auquier P2
1Hospital Regional Universitario Carlos Haya, Málaga, Spain, 2Timone University Hospital,
Marseille, France, 3Royal Melbourne Hospital, Melbourne, Australia, 4Neurological Rehabilitation
Center Quellenhof, Bad Wildbad, Germany, 5Dokuz Eylül University, Ýzmir, Turkey, 6Multiple
Sclerosis Unit, Department of Neuroscience AUSL, Bologna, Italy, 7Merck Serono S.A., Geneva,
Switzerland
OBJECTIVES: Quality of life (QoL) is an important measure in multiple sclerosis
(MS), complementing clinical assessments such as the Expanded Disability Status
Scale (EDSS). The MS International QoL (MusiQoL) questionnaire is a validated,
MS-specific instrument. This multicentre, observational study assessed respon-
siveness of MusiQoL versus the Short Form-36 version 2 (SF36v2) to changes in
EDSS score over 24 months in subjects with MS (18 years; EDSS 7.0;
treated/untreated). METHODS: MusiQoL, SF36v2 and EDSS scores were recorded at
baseline (BL) and 6-monthly intervals to month 24 (M24). Primary endpoint: change
in MusiQoL index score and effect size (ES) to M24. Secondary endpoints included
change in MusiQoL and SF36v2 scores and ES (BL–6-monthly assessments).
RESULTS: Six hundred subjects enrolled in 12 countries; 452 had evaluable BL and
M24 EDSS and MusiQoL index data. BL mean (SD) EDSS score was 2.9 (1.9), mean
(SD) MusiQoL index score was 68.5 (14.3), and mean (SD) MusiQoL subscale scores
ranged from 59.8 (25.0) to 85.5 (18.2). EDSS score worsened by M24 in 89 subjects
(19.7% vs expected 30%); mean (SD) change in MusiQoL index score was 0.30 (12.3)
in non-worsened (ES: 0.02) and –2.3 (11.6) in worsened (ES: –0.17) subjects. At M24,
larger (mean [SD]; ES) changes were seen in MusiQoL Relationship with Healthcare
System (–6.0 [16.9]; –0.40) and Sentimental and Sexual Life (–6.4 [26.2]; –0.22) sub-
scale scores for worsened subjects; in Psychological Well-Being (4.8 [21.6]; 0.20)
subscale score for non-worsened subjects; and in the SF36v2 physical component
(–2.5 [6.7]; –0.24), physical functioning (–3.3 [7.6]; –0.28), bodily pain (–3.1 [10.3];
–0.28) and emotional (–2.8 [14.1]; –0.22) subscale scores for worsened subjects.
CONCLUSIONS: MusiQoL index score detected poorer QoL in subjects with wors-
ening EDSS scores. Most MusiQoL scores decreased over 24 months in subjects with
more severe disability, indicating poorer QoL and confirming the utility of the
MS-specific MusiQoL questionnaire in rating QoL.
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OBJECTIVES: Walking impairment is recognised as one of the most distressing
disabilities for people with Multiple Sclerosis (MS) and is reported in approximately
75% of patients. The objective of this analysis is to assess the impact of impaired
walking on quality of life, and on direct and indirect costs to society. METHODS:
The NARCOMS registry is a voluntary MS patient self-report database operating
mainly in the US. The registry collects MS related data semi-annually through
web-based and mail questionnaires, and periodically administers additional sur-
veys on specific topics of interest, such as mobility. One of the main measures used
for assessing walking impairment is the Multiple Sclerosis Walking Scale 12
(MSWS12). The Patient Determined Disease Step (PDDS) scale is used to measure
the level of disease progression. NARCOMS data collection also addresses patient
reported quality of life through the EuroQol-5 Dimensions (EQ-5D) and the 12-item
Short-Form survey (SF-12), as well as patients’ physical activities, work life, and
healthcare resource use. We used descriptive statistics, and univariate analyses to
describe and quantify the cross-sectional relationship between walking impair-
ment and other patient outcomes. RESULTS: A total of 2276 patients were ran-
domly selected from the NARCOMS database, of which 1838 (81%) were female. The
sample population had a mean age of 46 years, and a mean PDDS score of 3.0.
Univariate analysis demonstrated that increases in MSWS-12 scores (decrease in
ambulation) were negatively correlated with quality of life as measured by EQ-5D.
An increase in MSWS-12 score was also associated with increases in visits to MS
neurologists and physiotherapists, increases in caregiver visits, as well as reduced
productivity. CONCLUSIONS: MS patients with less severe walking impairment
showed better quality of life, lower health care utilization and higher productivity.
Additional research using multivariate models should be encouraged to further
characterize the impact of impaired walking on MS patients.
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OBJECTIVES: To evaluate the evidence for quality of life (QoL) impairment, disabil-
ity, healthcare resource use, and economic burden associated with chronic daily
headache (CDH), particularly chronic migraine (CM).METHODS: Systematic review
and qualitative synthesis of studies of patients/subjects with CDH ( 15 headache
days/month) that included CM, reporting QoL or disability outcomes, healthcare
resource utilisation or associated direct costs. RESULTS: Thirty-four studies were
included: 25 of patients; 9 of subjects from the general population; 16 reporting QoL
and 14 reporting disability outcomes; 4 reporting on healthcare resource utilisation
and/or costs. Data were not amenable to statistical pooling. In studies reporting
QoL using SF-36 or SF-12 instruments: CDH was consistently associated with lower
QoL compared to normative/healthy control (5/5 studies) or episodic headache (EH)
(6/6 studies); 3/4 studies showed CDH with migraine was associated with lower QoL
than CDH without migraine; 3/5 studies showed CDH with medication overuse
headache (MOH) was associated with lower QoL than CDH without MOH; 4/4 stud-
ies suggested a significant negative QoL impact when CDH was with a comorbidity.
In studies reporting disability using the MIDAS instrument, CDH was consistently
associated with greater disability and productivity (D&P) loss than EH (7/7 studies),
1/2 studies showed CDH with migrainous features was associated with greater D&P
loss than CDH without migraine, 1/1 studies showed CDH with MOH was associ-
ated with greater D&P loss than CDH without MOH and 1/1 studies suggested a
significant negative impact when CDH was with a named comorbidity. In the two
most comprehensively reported economic studies, CDH was associated with more
consultations, more or longer hospitalisations and higher direct costs compared to
EH.CONCLUSIONS:The findings underline the disabling nature and QoL detriment
of CDH, and in particular of CM and CDH with MOH, and negative impact on work-
place productivity compared to other headache types.
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OBJECTIVES: A number of studies evaluated different predictors of health-related
quality of life (HRQOL) in children and adolescents with epilepsy, but the findings of
these studies were often contradictory and it was not possible to draw general
conclusions. Therefore, this review was organized with the aims to identify in a
systematic way the predictors of HRQOL in pediatric epilepsy.METHODS: Searches
of the literature in Pubmed, Scopus, and Web of Science, with searches of relevant
journals were performed. In total, 14 studies met the inclusion criteria (participant
aged up to 18 years, HRQOL was assessed with an epilepsy specific and/or generic
questionnaire/s, HRQOL predictors were identified using regression models, and
the study was published in a peer-review journal). The methodological quality of
the studies was assessed using predefined criteria. RESULTS: All identified studies
were cross-sectional with the quality scores ranging 7 (low) – 14 (high) points.
Strong evidence was found for age at epilepsy onset (younger age), a number of
antiepileptic drugs (AEDs), and parental depression as HRQOL predictors in both,
children and adolescents. Moderate evidence was found for attention problems,
overall intelligence (lower) and family (i. e. structure, parental anxiety, etc.). Spe-
cific to adolescents with epilepsy, seizure worry/concerns and side effects of AEDs
were found as strong predictors and epilepsy severity, while a number of AEDs as
moderate. Weak evidence and inconclusive data exist for other predictors (i.e.
social skills, duration of epilepsy, seizure frequency and severity, neuropsychiatric
comorbidity, side effects of AEDS, autonomy, social support, victimization, eco-
nomic status, and so forth). CONCLUSIONS: This systematic review identified age
at epilepsy onset, a number of AEDs, and parental depression as strong HRQOL
predictors in pediatric epilepsy, but specific to adolescents only, seizure worry/
concerns and side effects of AEDs were identified. Other predictors were of lesser
importance or were unimportant.
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OBJECTIVES: A growing body of evidence suggests that symptoms of attention-
deficit/hyperactivity disorder (ADHD) persist into adulthood and are associated
with ongoing impairments in quality of life (QoL). The objective of the study was to
identify the most commonly used QoL instruments in adults with ADHD and to
examine their psychometric properties. METHODS: A systematic literature review
was conducted to identify articles from 1990 to May 2011 using PUBMED and Pro-
QoLID. The search was limited to English language and key search terms included
but were not limited to ADHD, quality of life, psychometrics, questionnaires, and
adults. Identified articles were screened further to exclude clinical studies not
measuring QoL, review articles relating to ADHD and QoL, and studies with n 30.
RESULTS: The search yielded a total of 89 articles of which 16 were included in the
final review. The Adult ADHD Quality of Life (AAQoL) and the ADHD Impact Module
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